Tranzyme
Pharma TZYM today announced it is discontinuing and immediately
ending patient enrollment in DIGEST, a Phase 2b trial in diabetic patients
receiving TZP-102 for the management of symptoms of gastroparesis, due to
insufficient efficacy. The decision followed a planned interim futility
analysis, which examined patients' responsiveness to thrice daily oral dosing
of 10mg of TZP-102 or placebo at the end of weeks 4 and 8 of a 12 week trial.
The results are consistent with the findings of a prior Phase 2b trial in that
there was a very large placebo effect and no treatment effect.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in